Validation of the Self-Reported Psoriasis Treatment Convenience Scale (PTCS).
Convenience
Patient-reported outcome measures
Psoriasis
Treatment adherence and compliance
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
20
08
2021
accepted:
29
09
2021
pubmed:
15
10
2021
medline:
15
10
2021
entrez:
14
10
2021
Statut:
ppublish
Résumé
Adherence to topical treatments for psoriasis is reported to be poor. One key contributing factor is the inconvenience associated with formulations that may be greasy, time consuming to apply, and slow to absorb. There is a paucity of patient-reported outcome measures that evaluate psoriasis patients' perceptions of treatment convenience. The Psoriasis Treatment Convenience Scale (PTCS) was therefore developed and validated. Following a literature review of issues relating to convenience of topical treatments, important items were identified and a draft version of the PTCS was developed and underwent content validity testing (n = 20). The revised scale was included in a clinical trial of topical therapy (n = 794; NCT03308799), and psychometric testing was performed. The final questionnaire included five core items and one overall satisfaction question. In psychometric testing, the scale demonstrated stability across trial population, and good validity, reliability, and sensitivity. The PTCS is a new, reliable, sensitive, validated tool for the assessment of patient-reported treatment convenience. Use of the PTCS will facilitate evaluation of convenience as part of the clinical development of topical therapies, and thus may help to improve patient adherence and, therefore, treatment outcomes.
Identifiants
pubmed: 34648147
doi: 10.1007/s13555-021-00626-5
pii: 10.1007/s13555-021-00626-5
pmc: PMC8611138
doi:
Banques de données
ClinicalTrials.gov
['NCT03308799']
Types de publication
Journal Article
Langues
eng
Pagination
2077-2088Informations de copyright
© 2021. The Author(s).
Références
J Eur Acad Dermatol Venereol. 2005 Nov;19 Suppl 3:2-6
pubmed: 16274404
J Eur Acad Dermatol Venereol. 2013 Aug;27(8):931-51
pubmed: 23279069
J Dermatol. 2015 Apr;42(4):367-72
pubmed: 25720544
Br J Dermatol. 2017 Mar;176(3):667-676
pubmed: 27664406
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
J Dermatolog Treat. 2013 Feb;24(1):64-9
pubmed: 21797808
J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2253-2263
pubmed: 31454113
Arch Dermatol Res. 2018 May;310(4):271-319
pubmed: 29442137
Patient Prefer Adherence. 2016 Nov 17;10:2357-2367
pubmed: 27895471
J Dermatolog Treat. 2017 Aug;28(5):374-383
pubmed: 27786594
J Am Acad Dermatol. 2021 Feb;84(2):432-470
pubmed: 32738429
J Am Acad Dermatol. 2004 Aug;51(2):212-6
pubmed: 15280839
J Dermatolog Treat. 2017 Feb;28(1):32-39
pubmed: 27151546
Dermatology. 2016;232(3):334-43
pubmed: 27073875
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Drugs Dermatol. 2021 Apr 1;20(4):420-425
pubmed: 33852251
Ann Intern Med. 2018 Apr 3;168(7):ITC49-ITC64
pubmed: 29610923
J Dermatolog Treat. 2022 Feb;33(1):111-120
pubmed: 32091278
J Eur Acad Dermatol Venereol. 2012 May;26 Suppl 3:61-7
pubmed: 22512682
Br J Dermatol. 2017 Mar;176(3):759-764
pubmed: 27664969
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Psoriasis (Auckl). 2016 Aug 23;6:113-119
pubmed: 29387598